News

Photo

Trammo and Proton Partner on Green Ammonia

Global commodities trader Trammo and Dutch engineering group Proton Ventures have signed a Memorandum of Understanding (MoU) to cooperate on green ammonia – or what it termed NFuel – projects.

Photo

Polynt-Reichhold Up for Sale

The private equity owners of Polynt-Reichhold are seeking a sale of the specialty chemicals company, according to Reuters. Sources told the news agency that the value of any deal would likely be about €2.5 billion. An agreement is expected in the second quarter of this year.

Photo

DuPont, Chemours and Corteva Agree PFAS Fund

DuPont, along with Chemours, its former fluourochemicals and plastics business, and Corteva, the combined agrochemicals businesses of DuPont and Dow, have buried the hatchet and announced a cost-sharing agreement worth $4 billion to settle lawsuits over liability for discharges into US waterways of perfluorinated compounds such as PFAS and PFOA.

Photo

Univar Sells Distrupol to Private Equity

US-based multinational distributor Univar Solutions has agreed to sell its Distrupol subsidiary to GPD Companies, an affiliate of One Rock Capital Partners. Financial terms of the transaction, which is expected to close in the first half of 2021, were not disclosed.

Photo

LYB and Sinopec Finalize Ningbo JV Agreement

LyondellBasell (LYB) and China Petroleum & Chemical Corporation, better known as Sinopec, have finalized plans for a 50:50 joint venture to produce propylene oxide (PO) and styrene monomer (SM) in China for the domestic market. A non-binding Memorandum Understanding (MoU) was signed at the end of 2019.

Photo

EU Says Vaccine Makers Must Meet Commitments

For months, pandemic watchers have weighed in on the potential inequity of vaccine distribution, focusing mainly on the First World hoarding supplies that Third World wouldn’t receive. Unexpectedly, it is now Europe that has its boxing gloves on, ready to claw back what it sees as its fair share.

Photo

Starboard Seeks to Control Corteva, Oust CEO

Activist investor Starboard Value is seeking to take control of agricultural giant Corteva and replace its CEO, Jim Collins. Its nominations are up for election at Corteva’s 2021 annual meeting, for which a date has not yet been set.

Photo

Corbion Expands North American Lactic Acid

Dutch lactic acid specialist Corbion said it plans to increase its North American capacity by about 40% to meet growing demand for natural ingredients in multiple industries and reinforce its position as a leading worldwide supplier of lactic acid and derivatives.

Photo

OMV Hikes Burghausen Olefins Output

Austrian multinational energy and petrochemicals group OMV is expanding and modernizing the cracker and associated units at its Burghausen refinery in Germany. The measures will increase annual ethylene and propylene capacity by about 50,000 t/y, meeting growth in demand for petrochemical products both in the Bavarian Chemical Triangle and in international markets, OMV said.

Photo

Oqema Acquires Claus Nitsche & Sohn

German chemical distributor Oqema has acquired Hamburg, Germany-based compatriot Claus Nitsche & Sohn. Oqema said that with its focus on high-quality essential oils, natural flavors, fragrances ingredients and innovative ingredients solutions, the product scope of Claus Nitsche & Sohn is a perfect complement to the groups’s Flavour & Fragrance range.

Photo

Boehringer Ingelheim and Enara Bio in Cancer Pact

German drugmaker Boehringer Ingelheim and UK biotech Enara Bio have agreed to collaborate on the research and development of novel targeted cancer immunotherapies, leveraging Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT).

Photo

EU Fumes over Covid Vaccine Delivery Delays

Following initial euphoria over conditional marketing approval of two Covid-19 vaccines by the European Medicines Agency (EMA) in recent weeks, EU countries are turning sour on the first-past-the-post team, as Pfizer and BioNTec have informed authorities of what in a worst case scenario could be a massive shortfall in near-term deliveries.

Photo

DSM Establishes AI Biosciences Lab

DSM has established an Artificial Intelligence (AI) Lab for Biosciences in collaboration with Delft University of Technology (TU Delft) in the Netherlands.

Photo

US Recommits US to Paris and the WHO

After four years of Donald Trump rolling back Obama era environmental legislation, newly inaugurated US president Joe Biden on Jan. 20, his first day in office, rolled back a number of the Trump administration’s rollbacks.

Photo

Thermo Fisher Adds Strength in Covid Diagnostics

In another move to boost its position in diagnostics for Covid-19 and other infectious diseases, Thermo Fisher Scientific has signed a definitive agreement to acquire privately held molecular diagnostic company Mesa Biotech for $450 million in cash. The business will become part of its Life Sciences Solutions segment.

Photo

MEPS call for Vaccine Contract Transparency

Members of the European Parliament (EP) at a Jan. 19 plenary debate on the EU’s strategy for Covid-19 vaccine procurement and deployment for the most part expressed support for the common approach to purchasing a common supply for the 27 member states. At the same time, they urged more solidarity in access to inoculation and transparency in contracts with pharmaceutical companies.

Photo

Lonza to Sell two Capsule Sites to NextPharma

Swiss CDMO Lonza said it intends to unload two of its capsule production sites, at Ploermel, France, and Edinburgh, Scotland, for an undisclosed sum to London-based CDMO NextPharma. The proposed deal is subject to regulatory approval. According to reports, most of the affected employees are expected to transfer to the new owner.

Photo

W. R. Grace Ready to Talk on Sale to 40 North

W. R. Grace said it is willing to discuss a sale to 40 North Management after the private investment group raised its offer for the specialty chemical and materials firm to $65 per share, representing a value of $4.3 billion. Last November, 40 North made a first and unsolicited offer of $60 per share – or $4 billion – that Grace swiftly rejected as undervaluing the company.

Photo

Angelini Acquires Arvelle Therapeutics

Italy’s Angelini Pharma has entered into an agreement to acquire Swiss biopharma Arvelle Therapeutics in an all-cash transaction worth up to $960 million. The first $610 million will be paid following regulatory clearance of the deal, with a further $350 million paid if Arvelle’s epilepsy treatment cenobamate achieves certain revenue targets.

Photo

Pfizer-BioNTech Revamp Delays Europe’s doses

US drugmaker Pfizer and partner BioNTech have confirmed they will temporarily reduce Covid deliveries to Europe as Pfizer revamps its designated plant in Belgium to lift production capacity to 2 billion doses per year, as announced earlier.

Photo

Total Quits American Petroleum Institute

Total has announced it is leaving the American Petroleum Institute (API) in disagreement over the industry grouping’s climate positions. The French energy and chemicals group said it was unable to resolve differences with API over carbon pricing, subsidies for electric vehicles and the regulation of methane emissions.

Photo

Celanese Plans China LCP Polymerization Plant

Major liquid crystal polymer (LCP) producer Celanese has announced plans to build a world-scale, multi-phase polymerization plant in China to support significant growth for its Vectra and Zenite brand of polymers.

Photo

Azelis Enters Philippines with APKI and PSSI Buys

Azelis has agreed to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and Phil-Asiatic Supply & Services Inc. (PSSI), entering the Philippine market and significantly strengthening its footprint in Southeast Asia.

Photo

President-elect Biden Names new Warp Speed Chief

US president-elect Joe Biden, who will be sworn in on Jan. 20, has picked former FDA commissioner David Kessler to replace Moncef Slaoui as head of Operation Warp Speed, (OWS), the initiative started under president Donald Trump to accelerate the speed of Covid-19 vaccine development.

Photo

Catalent Acquires Acorda Assets

US-based CDMO Catalent has agreed to buy the powder inhaler spray drying, capsule manufacturing and packaging operations of Acorda Therapeutics, a biotech specializing in developing therapies for neurological disorders. Financial terms of the deal, which is expected to close in the first quarter of 2021, were not disclosed.

Photo

Nouryon Rebrands Industrial Chemicals as Nobian

Dutch chemical producer Nouryon has rebranded its wholly-owned industrial chemicals business as Nobian. The company said the change will allow the subsidiary to develop its integrated European value chain for essential base chemicals under its own name as Nouryon continues to focus on growing its leading position in global specialty chemicals.

Photo

Chinese Vaccines Provoke Discussion

Marching to the tune of the groundswell generated by Western Covid-19 vaccines approved, distributed and administered in the US, UK and the EU in recent weeks, Chinese vaccine manufacturers have been beating the drum for their candidates in countries in Latin America and the Middle East as well as at home.

Photo

TechnipFMC Resumes Separation Plans

TechnipFMC has restarted plans to split into two publicly traded companies: TechnipFMC and Technip Energies. The group put the separation plans on hold last March because of the coronavirus pandemic and turbulent financial markets.

Photo

Shell Invests in Canada Waste-to-Fuels Facility

Shell Canada has signed a deal to invest in Varennes Carbon Recycling, the first waste-to-low-carbon fuels plant in Quebec. Shell will take a 40% interest in the plant, which will use technology developed by Canadian clean tech company Enerkem.

Photo

Baxter to Supply Novavax Covid Vaccine in Germany

Baxter BioPharma Solutions has contracted to support production of US biotech Novavax’s new Covid-19 vaccine in Germany, when it is approved. Phase 3 data from late-stage trials is expected to be revealed soon.

10842 more News

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.